CARISMA Therapeutics Plunges 10.54% as HealthCap VII Sells Shares

On September 4, 2025, CARISMA Therapeutics experienced a significant drop of 10.54% in pre-market trading, reflecting a notable decline in investor sentiment.

HealthCap VII, L.P., a major investor in CARISMA Therapeutics, recently amended its Schedule 13D filing with the SEC. The amendment disclosed multiple share sales, including 147,884 shares on August 22, 92,900 shares on August 25, 80,201 shares on August 26, 110,214 shares on August 27, 82,194 shares on August 28, 91,852 shares on August 29, and a substantial 2,116,678 shares on September 2. These transactions resulted in HealthCap VII no longer holding more than 5% of the company's common stock as of September 2, 2025.

The amendment also corrected previously reported share counts and sale quantities, enhancing the accuracy of disclosure. This change in ownership concentration could potentially increase the float and alter the company's shareholder profile, which is materially relevant to governance and proxy dynamics. However, there is no operational or financial performance data included in this filing, and the material effect is limited to investor ownership and potential trading liquidity.